Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 12/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.41 |
| ▸ | LPL | P06858 | 5/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858753 | 0.87 | CHEK1 (0.41) | CHEK1LIPGLPLF11 | |
| SCHEMBL4856016 | 0.83 | CHEK1 (0.49) | CHEK1LIPGHIF1ACHEK2KIT | |
| SCHEMBL4853578 | 0.80 | ACVR1 (0.49) | CHEK1LIPGLPLMARK3 | |
| SCHEMBL4857019 | 0.79 | CHEK1 (0.53) | CHEK1LIPGLPLCHEK2AURKB | |
| SCHEMBL4856676 | 0.79 | PDGFRB (0.40) | CHEK1LIPGLPLCHEK2KIT | |
| SCHEMBL4852354 | 0.78 | CHEK1 (0.43) | CHEK1CHEK2KITMARK3MAPK1 | |
| SCHEMBL4855119 | 0.77 | CHEK1 (0.52) | CHEK1HIF1ACHEK2AURKB | |
| SCHEMBL4850599 | 0.77 | CHEK1 (0.52) | CHEK1HIF1ACHEK2AURKB | |
| SCHEMBL4859199 | 0.77 | CHEK1 (0.45) | CHEK1HIF1ACHEK2AURKB | |
| SCHEMBL4855296 | 0.77 | CHEK1 (0.56) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CHEK1 46/4885LIPG 2157/4885LPL 4075/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CHEK1 38/4885LIPG 1595/4885LPL 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.